Tufts Medical Center

Two Pediatric Medical Device Companies Receive Prestigious Award at MedTech Color Edition of Make Your Medical Device Pitch For Kids!™ Competition

Retrieved on: 
Monday, March 18, 2024
Pigment, Government, Mass General Brigham, Partnership, Risk, Patient, Research, African Americans, University, Pulse, Johns Hopkins University, Skin, Hospital, Community engagement, Ecosystem, Tufts Medical Center, Food, Blood, FDA, Medtech, Nursing

The event was held on March 15 at the University of California, Los Angeles, as part of the annual MedTech Color Pitch Competition during L.A. MedTech Week 2024, powered by BioscienceLA.

Key Points: 
  • The event was held on March 15 at the University of California, Los Angeles, as part of the annual MedTech Color Pitch Competition during L.A. MedTech Week 2024, powered by BioscienceLA.
  • The award-winning pediatric devices and companies are:
    Rubitection, Pittsburgh, Pa.– A low-cost skin assessment management tool for chronic wounds, Rubitection measures the properties of the skin.
  • – This patent-pending pulse oximeter device is designed specifically for pediatric populations to provide superior accuracy for all levels of skin pigmentation.
  • Advancements in pediatric medical devices continue to lag significantly behind those of adults, which is why APDI is focused on helping more pediatric medical device innovations achieve commercialization.

CENTEGIX® Launches Healthcare Safety Platform™ to Protect Frontline Workers

Retrieved on: 
Wednesday, March 27, 2024
Emergency, American Medical Association, Job satisfaction, Public health, Commissioner, Safety, School, SVP, Hospital, Health care, Magic, Emergency Nurses Association, Baystate Health, Former, Emergency medicine, Tufts Medical Center, American Osteopathic Association, Workplace, Nursing, ENA, Workplace violence, Commonwealth, Violence

ATLANTA, March 27, 2024 /PRNewswire/ -- CENTEGIX, the leading wearable safety technology provider, announces the launch of its CENTEGIX Safety Platform™ for hospitals and health systems, a cloud-based integrated solution designed to initiate the fastest response time to safety incidents across any hospital campus.

Key Points: 
  • Healthcare workers are some of the most threatened in the workplace as violence against healthcare staff continues to rise.
  • "The healthcare workers who protect us are among the most threatened in their workplace," said Brent Cobb, CEO of CENTEGIX.
  • The design of the Safety Platform is based on CENTEGIX's experience supporting frontline workers in various industries, predominantly K-12 educators, who also experience workplace safety concerns.
  • There isn't a magic fix-all for workplace violence in the healthcare setting, but with proactive and multi-layered safety plans, we can make improvements to better protect our healthcare staff.

Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists

Retrieved on: 
Wednesday, March 6, 2024
Consensus, HGD, Dysplasia, Goldblum, LGD, Cleveland Clinic, Marie Cassidy, CDX, Doctor of Philosophy, Intraepithelial neoplasia, Brigham and Women's Hospital, Barrett's esophagus, Hospital, Diagnosis, Mayo Clinic, Health, Patient, EAC, MPH, Clinical and Translational Gastroenterology, Esophageal cancer, Neoplasm, Yale School of Medicine, Esophagus, Gastroenterology, Tufts Medical Center, Medical imaging

WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.

Key Points: 
  • WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.
  • This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett's esophagus.
  • The pathologists were then asked to evaluate digital images from 60 WATS3D cases with BE.
  • "The significant variability among pathologists assessing Barrett's esophagus poses challenges for accurate diagnosis and treatment decisions, complicating patient care."

Dr. Ernst J. Schaefer, MD, joins Olaris Inc. as CLIA Laboratory Director

Retrieved on: 
Tuesday, March 5, 2024
Human nutrition, Bangladesh Technical Education Board, Ageing, Research, American Heart Association, Cardiovascular disease, Metabolomics, Health, Tufts University, Society, University, Health care, Medicine, Fluid mechanics, Policy, CLIA, Patient, Machine learning, Nutrition, Publication, Tufts Medical Center, Medical device

FRAMINGHAM, Mass., March 5, 2024 /PRNewswire-PRWeb/ -- Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, announced that Dr. Ernst Schaefer, a 30-year veteran in clinical diagnostics and an expert in developing monitoring tools to improve human health will be joining as CLIA Laboratory Director. Dr. Schaefer will continue in his role as laboratory director for Boston Heart Diagnostics, a company he co-founded in 2007, and at Clinical Enterprise, both in Framingham, MA.

Key Points: 
  • Olaris, Inc. a developer of metabolomic based precision diagnostics is pleased to announce that Dr. Ernst Schaefer, a 30 year veteran in clinical diagnostics and an expert in developing monitoring tools to improve human health will be joining as CLIA Laboratory Director.
  • Dr. Schaefer will continue in his role as laboratory director for Boston Heart Diagnostics, a company he co-founded in 2007, and at Clinical Enterprise, both in Framingham, MA.
  • "Ernie has one of the top clinical diagnostic minds in the world" said Dr. Elizabeth O'Day, CEO and Founder of Olaris.
  • I can't think of a better partner to bring Olaris' innovative diagnostics to the patients that need them".

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Retrieved on: 
Thursday, February 15, 2024
Cancer, OBGYN, Medicine, Education, MYGN, FACMG, Dillard University, Boston Market, Risk, Health, Myriad Genetics, FACOG, Genetics, Risk assessment, Associate, Genetic testing, Biology, Tufts Medical Center, Nursing

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.

Key Points: 
  • SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.
  • Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad.
  • “We’re thrilled to welcome Dallas to the Myriad team.
  • She is a passionate women’s health leader and patient advocate who is committed to advancing diversity, equity and inclusion in clinical care and education,” said Melissa Gonzales, president of women’s health, Myriad Genetics.

Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment

Retrieved on: 
Monday, February 12, 2024
Division, Sepsis, Infection, Blood, Physician, Investigator, SRL Diagnostics, BSI, Fungal infection, Bloodstream infections, Standard of care, Patient, Journal, MBBS, Tufts Medical Center, Medical imaging

The study, published in the Journal of Clinical Microbiology, titled, “ Culture-independent identification of bloodstream infections from whole blood: prospective evaluation in specimens of known infection status ,” was conducted at Tufts Medical Center in Boston, Mass.

Key Points: 
  • The study, published in the Journal of Clinical Microbiology, titled, “ Culture-independent identification of bloodstream infections from whole blood: prospective evaluation in specimens of known infection status ,” was conducted at Tufts Medical Center in Boston, Mass.
  • “In this study, the Investigators demonstrated that RaPID/BSI is not prone to false positive results, which is common with assays that rely on sequencing or standard molecular diagnostic techniques.
  • Importantly, they also demonstrated that the assay can detect ongoing infections missed by follow-up cultures.
  • RaPID/BSI correctly identified 58% more ongoing infections in patients with concurrent antimicrobial therapy than follow-up blood cultures.

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

Retrieved on: 
Friday, February 9, 2024
Tufts Medical Center, MD, Pain, Investigational New Drug, FDA, Food, DED, Principal investigator, IND, Clinical trial, Patient, NCP, Disease, Pharmaceutical industry

Notably, the initial IND submission to FDA proposed an open-label design for the clinical trial.

Key Points: 
  • Notably, the initial IND submission to FDA proposed an open-label design for the clinical trial.
  • Based on positive feedback from FDA, the Phase 2 study is now designed as a double-masked, randomized, 12-week placebo-controlled trial comparing OK-101 to placebo in NCP patients.
  • A total of 54 patients are planned for the study, with NCP disease confirmed via confocal microscopy.
  • OK-101 was also shown in a cutting-edge mouse model of NCP to significantly reduce ocular neuropathic pain.

IVI RMA Completes Acquisition of North American Operations of Eugin Group, Including Boston IVF and TRIO

Retrieved on: 
Wednesday, January 31, 2024
Health, General Health, Trio, Parent, IVI, Boston Medical Center, Patient, Dream, Fertility, TRIO, Harvard Medical School, Tufts Medical Center, Acquisition, Reproductive medicine, IVF

IVI RMA, one of the largest reproductive medicine groups in the world, today announced that it has completed the acquisition of North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO.

Key Points: 
  • IVI RMA, one of the largest reproductive medicine groups in the world, today announced that it has completed the acquisition of North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO.
  • In addition, Boston IVF brings multiple academic affiliations, including Harvard Medical School, Dartmouth Hitchcock Medical School, Boston University Medical Center, and Tufts Medical Center, among others.
  • “We are excited to officially welcome Boston IVF, its partner clinics and TRIO to the IVI RMA network,” added Lynn Mason, CEO of IVI RMA America.
  • “Together with IVI RMA, we will continue to pave the way for breakthroughs in fertility care.”

Calling all MedTech innovators: Up to $100,000 in federal grants to be awarded

Retrieved on: 
Monday, January 29, 2024
Research, Tufts Medical Center, Emergency, Health equity, Johns Hopkins University, PPN, Disaster, HRSA, MBA, Pandemic, Food, Microsoft, Human services, Mass, Organization, Marketing, Doctor of Philosophy, Small business, Mass General Brigham, Resource, Pharmaceutical industry

MCMs play a pivotal role in bolstering readiness and response capabilities to disasters arising from a broad spectrum of threats.

Key Points: 
  • MCMs play a pivotal role in bolstering readiness and response capabilities to disasters arising from a broad spectrum of threats.
  • An additional incentive is the potential for a second year of funding, based on the awardees’ progress in the first year.
  • Organizers are particularly interested in funding research and development (R&D) initiatives focused on pioneering early-stage medical technologies tailored to tackle disasters.
  • Such initiatives also have the potential to secure subsequent funding from other federal agencies operating within this domain.

Five finalists announced in Alliance for Pediatric Device Innovation’s “Make Your Medical Device Pitch For Kids!”™ competition in collaboration with MedTech Color

Retrieved on: 
Monday, January 8, 2024
Quality of life, Ecosystem, Hospital, UCLA, Food, Risk, Pigment, Medtech, FDA, Blood, MBA, Johns Hopkins University, Health, Pulse, Tufts Medical Center, Mass General Brigham, Doctor of Philosophy, Patient, Intelligence, Skin, Nursing

“We are delighted to partner with MedTech Color in this endeavor.”

Key Points: 
  • “We are delighted to partner with MedTech Color in this endeavor.”
    The five pediatric medical device finalists are:
    Kofimi Technology Inc. – Danvers, Mass.
  • – This patent-pending pulse oximeter device is designed specifically for pediatric populations to provide superior accuracy for all levels of skin pigmentation.
  • Finalists will compete on March 15 at the MedTech Color 4th Annual Pitch Competition at the UCLA campus.
  • Advancements in pediatric medical devices continue to lag significantly behind those of adults, which is why APDI is focused on helping more pediatric medical device innovations achieve commercialization.